Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Aurora Cannabis Secures Medical Pot Approval in Ireland

By Eric Volkman - Dec 3, 2019 at 7:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Canadian company will be a supplier in the initial phase of the country's recent legalization of medical cannabis.

A marijuana company with strong global ambitions, Aurora Cannabis ( ACB -6.39% ) has secured one of the first approvals for a medical cannabis product in the Republic of Ireland. The Canadian company announced Monday that it had been granted permission from the Irish Department of Health to import and sell its High CBD Oil Drops in the country.

In the press release trumpeting the news, Aurora said that High CBD Oil Drops is only the second product to receive such approval in Ireland.

Marijuana leaf with stethoscope.

Image source: Getty Images.

The country only recently opened the door for medical cannabis, and on an extremely limited basis. It is legalizing such medicine under its Medical Cannabis Access Programme (MCAP), a pilot program that will last for five years dating from the beginning of July. The law took effect shortly after it was signed into existence in June.

During this pilot phase of MCAP, the country intends cannabis to be a medicine of last resort, for patients "where conventional treatment has failed," in the words of the Department of Health. Additionally, medical cannabis use will be permitted only by those suffering one of three conditions: spasticity arising from multiple sclerosis, severe nausea/vomiting due to chemotherapy, and treatment-resistant epilepsy.

As with other countries that have legalized medical cannabis, such patients will be required to have a prescription from a qualified medical professional. Finally, the marijuana medicaments will be available only in licensed pharmacies.

Although these conditions are quite restrictive, Aurora nevertheless sounded a hopeful, crack-in-the-dam note about the future in its press release. "We look forward to more of Aurora's high-quality medicines being approved, so that more patients can benefit from the MCAP in Ireland," it wrote. "We will continue to work closely with all parties and state agencies to facilitate further availability."

This initial approval from a very fresh new market overseas dovetails with an important plank of the company's business strategy. The company has been building out its global footprint over the past few years, to the point that it is active in 24 countries outside of Canada. This makes Aurora the most international of all publicly traded North American marijuana stocks.

Despite this good news on the worldwide business front, the market did not respond positively; Aurora's share price dipped by more than 2% on Monday. It was a down day for marijuana stocks generally.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$6.01 (-6.39%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.